Fig. 2From: Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinomaOne-way sensitivity analyses of nivolumab plus ipilimumab in comparison with sunitinib in United States (a), United Kingdom (b) and China (c)Back to article page